ClinicalTrials.gg
CompletedNCT02693847Updated Feb 26, 2021

Natural History of Liver Cirrhosis Diagnosed by Transient Elastography in HIV/HCV-coinfected Patients

An observational study in Liver Cirrhosis, Hepatocellular Carcinoma and HIV, sponsored by Hospital Universitario de Valme. Completed at 8 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-26.

Sponsored by Hospital Universitario de Valme · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
446
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Liver Cirrhosis with a site in Spain — 16 open to participants now, 20 under way, 3 of them phase 3. Liver Cirrhosis · Spain.

Enrollment
12th of 26
446 · median 334
Started
2006
with 4 others
Observational
26 of 76
8 open now
Registered
32nd of 76
by date
Lead sponsor
2 of 76
Hospital Universitario de Valme

Among the 76 studies in Liver Cirrhosis with a site in Spain, this one is the 12th largest by enrollment of the 26 observational ones that give a count, is one of 5 that started in 2006, is one of 26 observational ones, and was the 32nd registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

16 of the 76 studies in Liver Cirrhosis with a site in Spain are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Liver Cirrhosis with a site in Spain, or all of them as a file.
02

Study summary

Prospective multicenter cohort recruiting consecutive patients from 7 hospitals in Andalusia, southern Spain, according to following criteria: 1) HIV infection, 2) Chronic active HCV infection, 3) Older than 18 years, 4) New diagnosis of liver cirrhosis on the basis of a liver stiffness above 14 kiloPascals, 5) No previous or concomitant decompensation of liver disease. Patients are prospectively followed-up according to a uniform protocol of care. Epidemiological, clinical and laboratory variables are periodically recorded. The primary outcomes are the emergence of a liver decompensation (including hepatocellular carcinoma), liver transplant or death. The predictors of these outcomes are analyzed.

03

Conditions studied

  • Liver Cirrhosis
  • Hepatocellular Carcinoma
  • HIV
  • HCV Coinfection

Keywords

  • HCV
  • HIV
  • Liver cirrhosis
  • Hepatocellular carcinoma
  • Liver transplant
  • Liver stiffness
  • Transient elastography
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

HIV/HCV-coinfected patients diagnosed of cirrhosis on the basis of a liver stiffness equal or greater than 14 kiloPascals

Inclusion criteria

  • Infection
  • chronic active infection (positive serum RNA HCV at inclusion)
  • New diagnosis of cirrhosis on the basis of a liver stiffness equal or greater than 14 kiloPascals.
  • No previous or concomitant decompensation of liver disease

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
446 participants (actual)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Proportion of patients who developed a first liver decompensation of cirrhosis during follow-up

    Episodes of liver decompensation will include those episodes of ascites, spontaneous bacterial peritonitis, portal hypertensive gastrointestinal bleeding, hepatorrenal syndrome, hepatic encephalopathy, hepatocellular carcinoma, non obstructive jaundice and acute on chronic liver failure. These episodes will be diagnosed according to standard definitions of clinical practice guidelines in the field (i.e. HCC diagnosis will be diagnosed according to AASLD criteria, spontaneous bacterial peritonitis and hepatorenal syndrome will be diagnosed following the EASL criteria, portal hypertensive gastrointestinal bleeding according Baveno VI consensus definition,...)

    Time frame: 3 years

Secondary outcomes

  1. Liver-related mortality

    Probability of liver-related death after enrollment

    Time frame: 3 Years

  2. All cause mortality

    Probability of death of any cause

    Time frame: 3 Years

07

Study locations

8 sites
  • Hospital de La Línea de la Concepción
    La Línea de la Concepción, Cádiz, Spain
  • Hospital Universitario de Puerto Real
    Puerto Real, Cádiz, Spain
  • Hospital Universitario Reina Sofía
    Córdoba, Spain
  • Complejo Hospitalario de Huelva
    Huelva, Spain
  • Complejo Hospitalario de Jaén
    Jaén, Spain
  • Hospital Universitario Virgen de la Victoria
    Málaga, Spain
  • Hospital Universitario de Valme
    Sevilla, 41011, Spain
  • Hospital Universitario Virgen Macarena
    Sevilla, 41011, Spain
08

References and documents

Publications

  • Merchante N, Rivero-Juarez A, Tellez F, Merino D, Jose Rios-Villegas M, Marquez-Solero M, Omar M, Macias J, Camacho A, Perez-Perez M, Gomez-Mateos J, Rivero A, Antonio Pineda J; Grupo Andaluz para el Estudio de las Hepatitis Viricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Hepatology. 2012 Jul;56(1):228-38. doi: 10.1002/hep.25616. Epub 2012 Jun 6. PubMed 22278746 ↗
  • Recio E, Macias J, Rivero-Juarez A, Tellez F, Merino D, Rios M, Marquez M, Omar M, Rivero A, Lorenzo S, Merchante N, Pineda JA. Liver stiffness correlates with Child-Pugh-Turcotte and MELD scores in HIV/hepatitis C virus-coinfected patients with cirrhosis. Liver Int. 2012 Jul;32(6):1031-2. doi: 10.1111/j.1478-3231.2012.02782.x. Epub 2012 Mar 9. No abstract available. PubMed 22405076 ↗
  • Pineda JA, Recio E, Camacho A, Macias J, Almodovar C, Gonzalez-Serrano M, Merino D, Tellez F, Rios MJ, Rivero A; Grupo Andaluz de Hepatitis Virica (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Liver stiffness as a predictor of esophageal varices requiring therapy in HIV/hepatitis C virus-coinfected patients with cirrhosis. J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):445-9. doi: 10.1097/QAI.0b013e3181acb675. PubMed 19487952 ↗
  • Merchante N, Tellez F, Rivero-Juarez A, Rios-Villegas MJ, Merino D, Marquez-Solero M, Omar M, Recio E, Perez-Perez M, Camacho A, Macias-Dorado S, Macias J, Lorenzo-Moncada S, Rivero A, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Viricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis. BMC Infect Dis. 2015 Dec 7;15:557. doi: 10.1186/s12879-015-1291-3. PubMed 26643257 ↗
  • Merchante N, Rivero-Juarez A, Tellez F, Merino D, Rios-Villegas MJ, Ojeda-Burgos G, Omar M, Macias J, Rivero A, Perez-Perez M, Raffo M, Lopez-Montesinos I, Marquez-Solero M, Gomez-Vidal MA, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Viricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis. AIDS. 2017 Feb 20;31(4):493-500. doi: 10.1097/QAD.0000000000001358. PubMed 27922855 ↗
  • Merchante N, Aldamiz-Echevarria T, Garcia-Alvarez M, Rivero-Juarez A, Macias J, Miralles P, Jimenez-Sousa MA, Mancebo M, Perez-Latorre L, Pineda-Tenor D, Berenguer J, Resino S, Pineda JA. Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients. J Viral Hepat. 2018 Feb;25(2):180-186. doi: 10.1111/jvh.12769. Epub 2017 Sep 7. PubMed 28783247 ↗
  • Merchante N, Rivero-Juarez A, Tellez F, Merino D, Rios-Villegas MJ, Villalobos M, Omar M, Rincon P, Rivero A, Perez-Perez M, Raffo M, Lopez-Montesinos I, Palacios R, Gomez-Vidal MA, Macias J, Pineda JA; Members of the HEPAVIR-Cirrhosis Study Group. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis. J Antimicrob Chemother. 2018 Sep 1;73(9):2435-2443. doi: 10.1093/jac/dky234. PubMed 29982683 ↗
  • Merchante N, Saroli Palumbo C, Mazzola G, Pineda JA, Tellez F, Rivero-Juarez A, Rios-Villegas MJ, Maurice JB, Westbrook RH, Judge R, Guaraldi G, Schepis F, Perazzo H, Rockstroh J, Boesecke C, Klein MB, Cervo A, Ghali P, Wong P, Petta S, De Ledinghen V, Macias J, Sebastiani G. Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease. Clin Infect Dis. 2020 Dec 31;71(11):2810-2817. doi: 10.1093/cid/ciz1181. PubMed 31813962 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Dec 2020 and a completion of Dec 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2015
First posted
Feb 29, 2016
Start
Feb 2006
Primary completionActual
Dec 2020
CompletionActual
Dec 2020
Last update
Feb 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02693847
Lead sponsor
Hospital Universitario de Valme
Collaborators
Hospital Universitario Virgen Macarena, Complejo Hospitalario Universitario de Huelva, Hospital de La Línea, Hospital Universitario Reina Sofia de Cordoba, Hospital Universitario Virgen de la Victoria, Complejo Hospitalario de Jaén, Hospital Universitario Puerto Real
Responsible party
Nicolás Merchante (MD, PhD, Hospital Universitario de Valme) — Principal investigator
First posted
Feb 29, 2016
Start date
Feb 2006
Primary completion
Dec 2020
Completion
Dec 2020
Last update
Feb 26, 2021

Study contacts

Nicolás Merchante, MD PhD
principal investigator · Andaluz Health Service

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion